Hofseth Biocare's study shows OxLDL-GP is key marker for tracking family history of cardio vascular desease.
M2 PHARMA-July 29, 2013-Hofseth Biocare's study shows OxLDL-GP is key marker for tracking family history of cardio vascular desease(C)2013 M2 COMMUNICATIONS
29 July 2013 - Norwegian biomarine company Hofseth Biocare ASA (OSL:HBC) has demonstrated in a study that oxidised low-density lipoprotein, oxLDL-GP, is a key cardio vascular desease (CVD) marker for tracking family history of the disease, the company said today.
The trial, comprising 188 patients, showed that serum oxLDL-GP levels can be associated with a family history of cardiovascular disease without any other clinical symptoms.
Other markers, including cholesterol and LDL/HDL, cannot predict the potential of cardiovascular disease based on family history, the firm noted.
Hofseth Biocare produces an enzymatically-liberated salmon oil (OmeGo) containing the complete lipid soluble factors in the whole fish. These OmeGo capsules have demonstrated ability to notably decrease oxLDL-GP levels and the company will initiate additional studies to explore the relationship between eating whole salmon, taking OmeGo capsules supplements and cardiovascular health.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 29, 2013|
|Previous Article:||Enigma Diagnostics to complete clinical validation, CE marking of FluAB-RSV diagnostic assay by end-2013.|
|Next Article:||Trovagene adopts RainDrop platform to create cell-free DNA assay.|